A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer von Ko, A H, Tempero, M A, Shan, Y-S, Su, W-C, Lin, Y-L, Dito, E, Ong, A, Wang, Y-W, Yeh, C G, Chen, L-T

Volltext

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study von Tempero, M., Oh, D.-Y., Tabernero, J., Reni, M., Van Cutsem, E., Hendifar, A., Waldschmidt, D.-T., Starling, N., Bachet, J.-B., Chang, H.-M., Maurel, J., Garcia-Carbonero, R., Lonardi, S., Coussens, L.M., Fong, L., Tsao, L.C., Cole, G., James, D., Macarulla, T.

Volltext

Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)—a randomized phase II trial of the AIO pancreatic cancer group von Seufferlein, T., Uhl, W., Kornmann, M., Algül, H., Friess, H., König, A., Ghadimi, M., Gallmeier, E., Bartsch, D.K., Lutz, M.P., Metzger, R., Wille, K., Gerdes, B., Schimanski, C.C., Graupe, F., Kunzmann, V., Klein, I., Geissler, M., Staib, L., Waldschmidt, D., Bruns, C., Wittel, U., Fichtner-Feigl, S., Daum, S., Hinke, A., Blome, L., Tannapfel, A., Kleger, A., Berger, A.W., Kestler, A.M.R., Schuhbaur, J.S., Perkhofer, L., Tempero, M., Reinacher-Schick, A.C., Ettrich, T.J.

Volltext

Lymphatic malformations: Review of current treatment von Perkins, Jonathan A., Manning, Scott C., Tempero, Richard M., Cunningham, Michael J., Edmonds, Joseph L., Hoffer, Fredric A., Egbert, Mark A.

Volltext

Pancreatic cancer treatment and research: an international expert panel discussion von Tempero, M.A., Berlin, J., Ducreux, M., Haller, D., Harper, P., Khayat, D., Schmoll, H.-J., Sobrero, A., Van Cutsem, E.

Volltext

Nerve growth factor regulates neurolymphatic remodeling during corneal inflammation and resolution von Fink, Darci M, Connor, Alicia L, Kelley, Philip M, Steele, Maria M, Hollingsworth, Michael A, Tempero, Richard M

Volltext

A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer von Kelley, R K, Hwang, J, Magbanua, M J M, Watt, L, Beumer, J H, Christner, S M, Baruchel, S, Wu, B, Fong, L, Yeh, B M, Moore, A P, Ko, A H, Korn, W M, Rajpal, S, Park, J W, Tempero, M A, Venook, A P, Bergsland, E K

Volltext

Health-related quality of life (HRQoL) in patients with early-stage pancreatic cancer (ESPC) receiving adjuvant or neoadjuvant chemotherapy (A/NAC): A systematic literature review... von Macarulla Mercade, T., Hendifar, A., Li, C.-P., Reni, M., Riess, H., Tempero, M.A., Dueck, A., Botteman, M.F., Deshpande, C., Lucas, E., Oh, D.-Y.

Volltext

The impact of COVID-19 on cancer care and oncology clinical research: an experts’ perspective von Sessa, C., Cortes, J., Conte, P., Cardoso, F., Choueiri, T., Dummer, R., Lorusso, P., Ottmann, O., Ryll, B., Mok, T., Tempero, M., Comis, S., Oliva, C., Peters, S., Tabernero, J.

Volltext

Immune modulatory effects of ibrutinib in pancreatic ductal adenocarcinoma von Sinha, M., Griffith, M., Betts, C., Choe, G., Sivagnanam, S., Cheung, A., Tamaki, W., Liu, E., Sudduth-Klinger, J., Vaccaro, G., Lopez, C., Fong, L., Coussens, L., Tempero, M.

Volltext

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer von KO, A. H, HWANG, J, VENOOK, A. P, ABBRUZZESE, J. L, BERGSLAND, E. K, TEMPERO, M. A

Volltext

Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study von Tempero, M., Oh, D., Macarulla, T., Reni, M., Van Cutsem, E., Hendifar, A., Waldschmidt, D., Starling, N., Bachet, J., Chang, H., Maurel, J., Lonardi, S., Coussens, L., Fong, L., Tsao, L., Cole, G., James, D., Tabernero, J.

Volltext

HALO 109-301: Phase III, randomized, double-blind, placebo-controlled study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients with previously untr... von Van Cutsem, E., Corrie, P.G., Ducreux, M.P., Sigal, D., Sahai, V., Oh, D.-Y., Bullock, A., Bang, Y.-J., Baron, A.D., Hendifar, A., Li, C.-P., Philip, P., Reni, M., Zalupski, M., Zheng, L., Berman, C., Chondros, D., Tempero, M.A.

Volltext

Analysis of patient screening in the phase III, international, randomized, open-label APACT trial von Reni, M., Winter, J., Tortora, G., Pelzer, U., Riess, H., Chang, H., O’Reilly, E., Oh, D., Diaz, I. Alés, Milella, M., Bendell, J., Garlipp, B., Tempero, M., Macarulla, T., Van Cutsem, E., Berlin, J., Goldstein, D., Lu, B., Jeanes, J., Philip, P.

Volltext

An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT)... von Reni, M., Riess, H., O’Reilly, E., Santoro, A., Park, J., Bekaii-Saab, T., Tempero, M., Shan, Y., Macarulla, T., Van Cutsem, E., Noel, M., Berlin, J., Biankin, A., Dhani, N., Frassineti, G., Goldstein, D., Romano, A., Bruchec, Y. Le, Philip, P.

Volltext

P-221PET-MR Imaging to Assess early treatment response in Pancreatic Adenocarcinoma von Collisson, E, Ohliger, M, Yeh, B, Kelly, D, Pampaloni, M, Ko, A, Tempero, M, Wang, Z

Volltext

AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma von DiMagno, Eugene P., Reber, Howard A., Tempero, Margaret A.

Volltext

Lymphatic endothelial lineage assemblage during corneal lymphangiogenesis von Connor, Alicia L, Kelley, Philip M, Tempero, Richard M

Volltext

HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer von Doherty, Gary J, Tempero, Margaret, Corrie, Pippa G

Volltext

Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model von ROWSE, G. J, TEMPERO, R. M, VANLITH, M. L, HOLLINGSWORTH, M. A, GENDLER, S. J

Volltext